ABIOMED, Inc. (NASDAQ:ABMD) Shares Sold by Altman Advisors Inc.

Altman Advisors Inc. trimmed its holdings in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 49.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,105 shares of the medical equipment provider’s stock after selling 2,025 shares during the period. Altman Advisors Inc.’s holdings in ABIOMED were worth $374,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Nomura Holdings Inc. increased its holdings in shares of ABIOMED by 95.5% in the 2nd quarter. Nomura Holdings Inc. now owns 7,709 shares of the medical equipment provider’s stock worth $2,043,000 after acquiring an additional 3,765 shares during the period. Amundi Pioneer Asset Management Inc. increased its holdings in shares of ABIOMED by 314.3% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 648,206 shares of the medical equipment provider’s stock worth $185,120,000 after acquiring an additional 491,750 shares during the period. Kayne Anderson Rudnick Investment Management LLC increased its holdings in shares of ABIOMED by 78.6% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 13,934 shares of the medical equipment provider’s stock worth $3,980,000 after acquiring an additional 6,134 shares during the period. Bessemer Group Inc. increased its holdings in shares of ABIOMED by 132,163.4% in the 2nd quarter. Bessemer Group Inc. now owns 148,135 shares of the medical equipment provider’s stock worth $38,588,000 after acquiring an additional 148,023 shares during the period. Finally, Nuveen Asset Management LLC increased its holdings in shares of ABIOMED by 17,845.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 197,759 shares of the medical equipment provider’s stock worth $51,514,000 after acquiring an additional 196,657 shares during the period. 91.10% of the stock is currently owned by institutional investors.

A number of analysts recently weighed in on ABMD shares. Guggenheim cut shares of ABIOMED from a “buy” rating to a “neutral” rating in a report on Friday, August 2nd. BidaskClub cut shares of ABIOMED from a “sell” rating to a “strong sell” rating in a report on Saturday, August 31st. Morgan Stanley cut shares of ABIOMED from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $325.00 to $215.00 in a report on Thursday, August 1st. ValuEngine raised shares of ABIOMED from a “sell” rating to a “hold” rating in a report on Wednesday, September 4th. Finally, BTIG Research cut shares of ABIOMED from a “buy” rating to a “neutral” rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $316.50.

ABMD traded down $0.07 on Wednesday, reaching $159.42. The company had a trading volume of 29,571 shares, compared to its average volume of 630,610. The company has a fifty day moving average of $184.98 and a 200-day moving average of $240.80. The company has a market capitalization of $7.24 billion, a P/E ratio of 44.30, a PEG ratio of 1.47 and a beta of 0.41. ABIOMED, Inc. has a one year low of $158.45 and a one year high of $427.70.

ABIOMED (NASDAQ:ABMD) last announced its earnings results on Thursday, August 1st. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.01. The firm had revenue of $207.70 million during the quarter, compared to analyst estimates of $210.96 million. ABIOMED had a net margin of 32.35% and a return on equity of 19.84%. ABIOMED’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.95 EPS. Sell-side analysts forecast that ABIOMED, Inc. will post 4.28 EPS for the current fiscal year.

In related news, COO David M. Weber sold 8,095 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $206.26, for a total value of $1,669,674.70. Following the completion of the transaction, the chief operating officer now owns 132,913 shares in the company, valued at approximately $27,414,635.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.40% of the company’s stock.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Read More: What is the Difference Between Common Shares and Convertible Shares?

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.